Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AT-527 Formulation 1 Dose 1 | Experimental |
| |
| AT-527 Formulation 2 Dose 1 | Experimental |
| |
| AT-527 Formulation 2 Dose 2 | Experimental |
| |
| AT-527 Formulation 1 Dose 3 | Experimental |
| |
| AT-527 Formulation 2 Dose 3 | Experimental |
| |
| AT-527 Formulation 2 Dose 1 Fast/Fed | Experimental |
| |
| AT-527 Formulation 2 Dose 3 Fast/Fed | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AT-527 Formulation 1 | Drug | AT-527 Formulation 1 (R07496998) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events. | Day 10 |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK) of AT-527 | Maximum plasma concentration (Cmax) | Days 1 and 5 |
| Pharmacokinetics (PK) of AT-527 | Area under the concentration-time curve (AUC) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Atea Study Site | Montreal | Quebec | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Comparator | Other | Placebo Comparator |
|
| AT-527 Formulation 2 | Drug | AT-527 Formulation 2 (R07496998) |
|
| Days 1 and 5 |